Oragenics, Inc.(OGEN)Earnings, Financials & Key Ratios
OGEN•AMEX
$0.62
$3M mkt cap·Price updated May 6, 2026
AboutOragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Show more
- Revenue$0
- EBITDA-$9M+11.2%
- Net Income-$9.84B-93035.5%
- EPS (Diluted)-4.56-185.0%
- ROE-237.71%+66.8%
- ROIC-0.34%
- Debt/Equity0.03
- Interest Coverage-11.91+96.6%
OGEN Key Insights
Oragenics, Inc. (OGEN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Share count reduced 67.4% through buybacks
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Weak momentum: RS Rating 9 (bottom 9%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
OGEN Price & Volume
Oragenics, Inc. (OGEN) stock price & volume — 10-year historical chart
Loading chart...
OGEN Growth Metrics
Oragenics, Inc. (OGEN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM6.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-338.1%
Return on Capital
10 Years-178.75%
5 Years-222.85%
3 Years-323.52%
Last Year-0.19%
OGEN Peer Comparison
Oragenics, Inc. (OGEN) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SIGA | 336.57M | 4.70 | 14.24 | -31.8% | 24.64% | 0% | 0 | |
 ADMA | 2.46B | 10.08 | 16.80 | 19.63% | 28.8% | 34.98% | 0.17 | |
 NVAX | 1.53B | 9.36 | 3.69 | 64.69% | -14.73% | |||
 DYAI | 27.51M | 0.76 | -3.80 | 20.58% | -279.56% | -281.83% | 2.05 | |
 VXRT | 179.17M | 0.75 | 10.64 | 7.27% | 6.88% | 33.83% | 0.10 | |
 PRPH | 5.82M | 0.14 | -0.05 | -84.75% | -38.72% | -6.08% | 3.34 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 ORMP | 160.11M | 3.92 | -8.34 | -100% | -12.08% | -15.73% | 0.00 |
Compare OGEN vs Peers
Oragenics, Inc. (OGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OGEN Income Statement
Oragenics, Inc. (OGEN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 65.8K | 30.11K | 62.62K | 22.11M | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -65.8K▲ 0% | -30.11K▲ 54.2% | -62.62K▼ 108.0% | -22.11M▼ 35203.2% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | 12.31% | 54.24% | -107.98% | -35203.19% | 100% | - | - | - | - |
| Operating Expenses | 6.72M | 9.99M | 15.88M | 4.53M | 15.77M | 14.42M | 20.9M | 10.56M | 9.36M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.18M | 4.02M | 3.76M | 4.53M | 5.27M | 4.48M | 5.45M | 6.44M | 6.97B |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 3.54M | 5.97M | 12.12M | 22.11M | 10.59M | 10.07M | 15.49M | 4.11M | 2.39B |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -3.1K | 446 | 2K | -22.11M | -86.99K | -131.52K | -37.65K | 0 | -9.35B |
| Operating Income | -6.72M▲ 0% | -9.99M▼ 48.8% | -15.88M▼ 58.9% | -26.64M▼ 67.8% | -15.77M▲ 40.8% | -14.42M▲ 8.6% | -20.9M▼ 45.0% | -10.56M▲ 49.5% | -9.36M▲ 11.3% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 21.35% | -48.76% | -58.88% | -67.79% | 40.8% | 8.56% | -44.96% | 49.49% | 11.33% |
| EBITDA | -6.65M | -9.96M | -15.82M | -26.59M | -15.73M | -14.38M | -20.88M | -10.54M | -9.36M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 21.43% | -49.78% | -58.73% | -68.13% | 40.84% | 8.61% | -45.22% | 49.52% | 11.16% |
| D&A (Non-Cash Add-back) | 65.8K | 30.11K | 62.62K | 51.7K | 41.24K | 44.67K | 27.39K | 0 | 0 |
| EBIT | -6.72M | -9.91M | -15.56M | -26.64M | -15.7M | -14.27M | -20.63M | -10.54M | -9.36M |
| Net Interest Income | -206.11K | 80.74K | 312.71K | 78.61K | 60.09K | 120.8K | 179.8K | 16.07K | -603.7K |
| Interest Income | 10.22K | 86.53K | 320.01K | 89.29K | 75.85K | 135.9K | 179.8K | 45.9K | 182.23K |
| Interest Expense | 216.33K | 5.79K | 7.3K | 10.69K | 15.76K | 15.1K | 0 | 29.83K | 785.93K |
| Other Income/Expense | -13.21K | 80K | 311.57K | 210.76K | 59.4K | 132.38K | 249.17K | -9.1K | -616.89K |
| Pretax Income | -6.73M▲ 0% | -9.91M▼ 47.3% | -15.57M▼ 57.0% | -26.43M▼ 69.8% | -15.71M▲ 40.6% | -14.29M▲ 9.1% | -20.66M▼ 44.6% | -10.57M▲ 48.8% | -9.98M▲ 5.6% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 13.21K | -80K | 7.76K | 0 | 0 | 0 | 0 | 0 | -136.91K |
| Effective Tax Rate % | -0.2% | 0.81% | -0.05% | 0% | 0% | 0% | 0% | 0% | 1.37% |
| Net Income | -6.73M▲ 0% | -9.91M▼ 47.3% | -15.57M▼ 57.1% | -26.43M▼ 69.7% | -15.71M▲ 40.6% | -14.29M▲ 9.1% | -20.66M▼ 44.6% | -10.57M▲ 48.8% | -9.84B▼ 93035.5% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 4.02% | -47.28% | -57.09% | -69.71% | 40.56% | 9.06% | -44.56% | 48.84% | -93035.54% |
| Net Income (Continuing) | -6.73M | -9.91M | 0 | -26.43M | -15.71M | -14.29M | -20.66M | -10.57M | -9.84M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -81.99▲ 0% | -45.62▲ 44.4% | -22.10▲ 51.6% | -28.05▼ 26.9% | -8.09▲ 71.2% | -7.11▲ 12.1% | -9.18▼ 29.1% | -1.60▲ 82.6% | -4.56▼ 185.0% |
| EPS Growth % | 13.08% | 44.36% | 51.56% | -26.92% | 71.16% | 12.11% | -29.11% | 82.57% | -185% |
| EPS (Basic) | -81.99 | -45.62 | -22.10 | -28.05 | -8.09 | -7.11 | -9.18 | -1.60 | -4.56 |
| Diluted Shares Outstanding | 82.1K | 217.32K | 704.73K | 942.19K | 1.88M | 2.01M | 2.25M | 6.62M | 2.16M |
| Basic Shares Outstanding | 82.1K | 217.32K | 704.73K | 942.19K | 1.88M | 2.01M | 2.25M | 6.62M | 2.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
OGEN Balance Sheet
Oragenics, Inc. (OGEN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.19M | 21.93M | 18.84M | 17.98M | 27.71M | 14.29M | 3.87M | 1.47M | 10.07B |
| Cash & Short-Term Investments | 6.17M | 20.21M | 18.27M | 17.64M | 27.27M | 11.43M | 3.48M | 864.84K | 8.4B |
| Cash Only | 6.17M | 20.21M | 18.27M | 17.64M | 27.27M | 11.43M | 3.48M | 864.84K | 4.4B |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4B |
| Accounts Receivable | 0 | 0 | 0 | 0 | 6.99K | 0 | 0 | 0 | 53.08M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.03M | 1.72M | 0 | 0 | 0 | 0 | 0 | 0 | 1.61B |
| Total Non-Current Assets | 21.66K | 116.28K | 914.65K | 697.85K | 523.59K | 468.5K | 1.1M | 0 | 0 |
| Property, Plant & Equipment | 21.66K | 116.28K | 914.65K | 697.85K | 523.59K | 468.5K | 9.81K | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 1.09M | 0 | 0 |
| Total Assets | 7.21M▲ 0% | 22.05M▲ 205.6% | 19.75M▼ 10.4% | 18.68M▼ 5.4% | 28.23M▲ 51.1% | 14.76M▼ 47.7% | 4.97M▼ 66.3% | 1.47M▼ 70.4% | 10.07B▲ 683614.5% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 67.43% | 205.61% | -10.42% | -5.43% | 51.13% | -47.72% | -66.35% | -70.35% | 683614.47% |
| Total Current Liabilities | 898.52K | 1.17M | 1.85M | 1.34M | 1.45M | 1.6M | 1.8M | 1.68M | 227.35M |
| Accounts Payable | 618.36K | 828.71K | 1.21M | 330.38K | 854.98K | 246.69K | 1.24M | 1.14M | 1.56M |
| Days Payables Outstanding | 3.43K | 10.05K | 7.04K | 5.45 | - | - | - | - | - |
| Short-Term Debt | 80.48K | 124.21K | 143.86K | 228.23K | 303.42K | 267.64K | 312.7K | 328.53K | 227.35M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 42.96K | 39.61K | 143.09K | 158.72K | 57.73K | 843.96K | 0 | 202.83K | -1.56M |
| Current Ratio | 8.01x | 18.79x | 10.18x | 13.40x | 19.17x | 8.95x | 2.15x | 0.87x | 44.28x |
| Quick Ratio | 8.01x | 18.79x | 10.18x | 13.40x | 19.17x | 8.95x | 2.15x | 0.87x | 44.28x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 698.84K | 952.92K | 670.69K | 493.79K | 299.52K | 152.44K | 0 | 0 | 1.56B |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 670.69K | 493.79K | 299.52K | 152.44K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.56B |
| Total Liabilities | 898.52K | 1.17M | 2.52M | 1.84M | 1.74M | 1.75M | 1.8M | 1.68M | 1.79B |
| Total Debt | 80.48K | 124.21K | 979.65K | 898.92K | 797.21K | 624.53K | 322.51K | 328.53K | 227.35M |
| Net Debt | -6.09M | -20.08M | -17.29M | -16.74M | -26.47M | -10.8M | -3.16M | -536.31K | -4.17B |
| Debt / Equity | 0.01x | 0.01x | 0.06x | 0.05x | 0.03x | 0.05x | 0.10x | - | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -31.06x | -1727.27x | -2175.07x | -2493.35x | -1000.95x | -954.83x | - | -353.99x | -11.91x |
| Total Equity | 6.32M▲ 0% | 20.88M▲ 230.6% | 17.23M▼ 17.5% | 16.84M▼ 2.2% | 26.49M▲ 57.2% | 13.01M▼ 50.9% | 3.17M▼ 75.6% | -211.88K▼ 106.7% | 8.28B▲ 3908543.3% |
| Equity Growth % | 112.98% | 230.6% | -17.48% | -2.25% | 57.24% | -50.88% | -75.65% | -106.69% | 3908543.26% |
| Book Value per Share | 76.93 | 96.09 | 24.45 | 17.88 | 14.07 | 6.48 | 1.41 | -0.03 | 3839.18 |
| Total Shareholders' Equity | 6.32M | 20.88M | 17.23M | 16.84M | 26.49M | 13.01M | 3.17M | -211.88K | 8.28M |
| Common Stock | 4.93K | 29.43K | 46.13K | 91.77K | 116.39K | 2.02K | 3.08K | 12.57K | 4.27K |
| Retained Earnings | -101.4M | -111.37M | -127.35M | -154.44M | -171.27M | -185.56M | -206.22M | -216.79M | -226.63M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.58M | -1.61M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OGEN Cash Flow Statement
Oragenics, Inc. (OGEN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -6.36M | -9.08M | -13.01M | -16.95M | -13.47M | -15.23M | -7.29M | -8.6M | -9.25B |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 10.05% | -42.68% | -43.32% | -30.28% | 20.54% | -13.05% | 52.12% | -17.92% | -107448.87% |
| Net Income | -6.73M | -9.91M | -15.57M | -26.43M | -15.71M | -14.29M | -20.66M | -10.57M | -9.84B |
| Depreciation & Amortization | 65.8K | 30.11K | 62.62K | 51.7K | 41.24K | 44.67K | 27.39K | 0 | 771.44M |
| Stock-Based Compensation | 560.48K | 1.02M | 553K | 1.49M | 1.69M | 742.2K | 1.02M | 516.05K | 642.36M |
| Deferred Taxes | 0 | 0 | 0 | 0 | -1.77M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -70.49K | 12K | 12K | 7.9M | 1.77M | -10.96K | 10.3M | 0 | -816.84M |
| Working Capital Changes | -188.12K | -228.14K | 1.93M | 37.02K | 512.14K | -1.72M | 2.02M | 1.45M | -857.22K |
| Change in Receivables | 0 | 0 | 0 | 0 | -6.99K | 6.99K | 0 | 0 | -53.08K |
| Change in Inventory | 0 | 0 | 0 | 0 | 6.99K | 0 | 0 | 0 | 0 |
| Change in Payables | 525.78K | 225.31K | 0 | 0 | 10.55K | 0 | 0 | -119.8K | 203.14K |
| Cash from Investing | 0 | -124.73K | -25.21K | 0 | -43.88K | -115.52K | -936.28K | 0 | 0 |
| Capital Expenditures | 0 | -124.73K | -25.21K | 0 | -43.88K | -127.52K | -1M | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 12K | 63.72K | 0 | 0 |
| Cash from Financing | 8.45M | 23.25M | 11.1M | 16.32M | 23.14M | -494.92K | 283.88K | 5.98M | 16.78B |
| Debt Issued (Net) | 2.24M | 0 | -252.93K | -197.33K | -524.98K | -564.21K | -566.05K | -693.11K | -872.62K |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K | 1000K | 69.29K | 849.93K | 1000K | 1000K |
| Dividends Paid | 0 | -58.67K | 0 | 0 | -1.12M | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -5.64M | 0 | 0 | 0 | 0 |
| Other Financing | 6.21M | 23.31M | 11.35M | 5.18M | 1.12M | 0 | 0 | 0 | 16.76B |
| Net Change in Cash | 2.09M▲ 0% | 14.04M▲ 573.3% | -1.94M▼ 113.8% | -628.42K▲ 67.6% | 9.63M▲ 1631.8% | -15.84M▼ 264.5% | -7.94M▲ 49.8% | -2.62M▲ 67.0% | 7.53B▲ 287838.1% |
| Free Cash Flow | -6.36M▲ 0% | -9.2M▼ 44.6% | -13.04M▼ 41.6% | -16.95M▼ 30.0% | -13.51M▲ 20.3% | -15.36M▼ 13.6% | -8.29M▲ 46.0% | -8.6M▼ 3.7% | -9.25B▼ 107448.9% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 10.4% | -44.64% | -41.65% | -30.03% | 20.28% | -13.63% | 46.01% | -3.7% | -107448.87% |
| FCF per Share | -77.51 | -42.36 | -18.50 | -17.99 | -7.18 | -7.64 | -3.68 | -1.30 | -4286.54 |
| FCF Conversion (FCF/Net Income) | 0.95x | 0.92x | 0.84x | 0.64x | 0.86x | 1.07x | 0.35x | 0.81x | 0.94x |
| Interest Paid | 0 | 0 | 7.3K | 10.02K | 0 | 9.29K | 30.59K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OGEN Key Ratios
Oragenics, Inc. (OGEN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -182.24% | -145.04% | -72.9% | -81.72% | -155.13% | -72.52% | -72.35% | -255.36% | -714.95% | -237.71% |
| Return on Invested Capital (ROIC) | - | -2184.64% | -1457.5% | -3213.29% | -84585% | -19448.14% | -972.3% | -1416.19% | - | -0.34% |
| Debt / Equity | 0.02x | 0.01x | 0.01x | 0.06x | 0.05x | 0.03x | 0.05x | 0.10x | - | 0.03x |
| Interest Coverage | -2075.44x | -31.06x | -1727.27x | -2175.07x | -2493.35x | -1000.95x | -954.83x | - | -353.99x | -11.91x |
| FCF Conversion | 1.01x | 0.95x | 0.92x | 0.84x | 0.64x | 0.86x | 1.07x | 0.35x | 0.81x | 0.94x |
| Revenue Growth | -100% | - | - | - | - | - | - | - | - | - |
OGEN Frequently Asked Questions
Oragenics, Inc. (OGEN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Oragenics, Inc. (OGEN) grew revenue by 0.0% over the past year. Growth has been modest.
Oragenics, Inc. (OGEN) reported a net loss of $9.8M for fiscal year 2025.
Dividend & Returns
Oragenics, Inc. (OGEN) has a return on equity (ROE) of -237.7%. Negative ROE indicates the company is unprofitable.
Oragenics, Inc. (OGEN) had negative free cash flow of $9.25B in fiscal year 2025, likely due to heavy capital investments.
Explore More OGEN
Oragenics, Inc. (OGEN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates